A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5248
- Registration Number
- NCT02242396
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6336
- Registration Number
- NCT02242838
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT02242279
Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5018
- Registration Number
- NCT02242851
Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 95
- Registration Number
- NCT02242240
Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1527
- Registration Number
- NCT02242864
Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13248
- Registration Number
- NCT02242383
Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort
Phase 3
Completed
- Conditions
- Abdominal Pain
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT02242305
Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19805
- Registration Number
- NCT02242331
Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 527
- Registration Number
- NCT02242292